메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 25, Issue 29, 2007, Pages 4689-4690
Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: A claim without evidence [1]
Author keywords

[No Author keywords available]
Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PREDNISONE; RAZOXANE; VINCRISTINE;
EID: 35648964243     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.6888     Document Type: Letter
Times cited : (32)
References (8)
  • 1
    • 33947542048 scopus 로고    scopus 로고
    • Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease
    • Tebbi CK, London WB, Friedman D, et al: Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 25:493-500, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 493-500
    • Tebbi, C.K.1    London, W.B.2    Friedman, D.3
  • 2
    • 0037445124 scopus 로고    scopus 로고
    • Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: A case-control study by the Societe Francaise d'Oncologie Pediatrique
    • Le Deley MC, Leblanc T, Shamsaldin A, et al: Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: A case-control study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 21:1074-1081, 2003
    • (2003) J Clin Oncol , vol.21 , pp. 1074-1081
    • Le Deley, M.C.1    Leblanc, T.2    Shamsaldin, A.3
  • 3
    • 30444458820 scopus 로고    scopus 로고
    • Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: A Pediatric Oncology Group (POG) study
    • Tebbi CK, Mendenhall N, London WB, et al: Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: A Pediatric Oncology Group (POG) study. Pediatric Blood Cancer 46:198-202, 2006
    • (2006) Pediatric Blood Cancer , vol.46 , pp. 198-202
    • Tebbi, C.K.1    Mendenhall, N.2    London, W.B.3
  • 4
    • 33645294906 scopus 로고    scopus 로고
    • Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy
    • Marty M, Espie M, Llombart A, et al: Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol 17:614-622, 2006
    • (2006) Ann Oncol , vol.17 , pp. 614-622
    • Marty, M.1    Espie, M.2    Llombart, A.3
  • 5
    • 33846882147 scopus 로고    scopus 로고
    • Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia
    • Moghrabi A, Levy DE, Asselin B, et al: Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109:896-904, 2007
    • (2007) Blood , vol.109 , pp. 896-904
    • Moghrabi, A.1    Levy, D.E.2    Asselin, B.3
  • 6
    • 18744377282 scopus 로고    scopus 로고
    • Dexrazoxane: A review of its use for cardioprotection during anthracycline chemotherapy
    • Cvetkovic RS, Scott LJ: Dexrazoxane: A review of its use for cardioprotection during anthracycline chemotherapy. Drugs 65:1005-1024, 2005
    • (2005) Drugs , vol.65 , pp. 1005-1024
    • Cvetkovic, R.S.1    Scott, L.J.2
  • 7
    • 85088001597 scopus 로고    scopus 로고
    • Dexrazoxane and the ASCO Guidelines for the use of chemotherapy and radiotherapy protectants: A critique
    • Hellmann K: Dexrazoxane and the ASCO Guidelines for the use of chemotherapy and radiotherapy protectants: A critique. J Clin Oncol 18:2004-2005, 2000
    • (2000) J Clin Oncol , vol.18 , pp. 2004-2005
    • Hellmann, K.1
  • 8
    • 33846912251 scopus 로고    scopus 로고
    • Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: Risk factors for leukemia and myelodysplastic syndrome after breast cancer
    • Le Deley MC, Suzan F, Cutuli B, et al: Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: Risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 25:292-300, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 292-300
    • Le Deley, M.C.1    Suzan, F.2    Cutuli, B.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.